Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis.

Andrew BlauveltLeon KircikKim A PappEric L SimpsonJonathan Ian SilverbergBrian S KimShawn G KwatraMichael E KuligowskiMay E VenturanzaShaoceng WeiJacek Cezary Szepietowski

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2022)

Ruxolitinib cream demonstrated rapid improvement in itch in patients with mild to moderate AD that was sustained for 8 weeks. Significantly more patients applying ruxolitinib cream achieved itch NRS2 within approximately 12 h and itch NRS4 by Day 2 versus vehicle.

Keyphrases

atopic dermatitis
end stage renal disease
chronic kidney disease
newly diagnosed
prognostic factors
loop mediated isothermal amplification
patient reported outcomes
gestational age
preterm birth
quantum dots